Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Research Report 2024
Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.
According to Mr Accuracy reports new survey, global Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to reach US$ 2122.1 million in 2029, increasing from US$ 751 million in 2022, with the CAGR of 16.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glucagon-like Peptide-2 (GLP-2) Agonist market research.
The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market's success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glucagon-like Peptide-2 (GLP-2) Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Takeda Pharmaceuticals
Segment by Type
Gattex
Revestive
Hospital
Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Glucagon-like Peptide-2 (GLP-2) Agonist report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to reach US$ 2122.1 million in 2029, increasing from US$ 751 million in 2022, with the CAGR of 16.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glucagon-like Peptide-2 (GLP-2) Agonist market research.
The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market's success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glucagon-like Peptide-2 (GLP-2) Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda Pharmaceuticals
Segment by Type
Gattex
Revestive
Segment by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Glucagon-like Peptide-2 (GLP-2) Agonist report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices